Navigation Links
Vaccine first to show improved survival rates for metastatic melanoma
Date:6/3/2011

(CHICAGO) For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

The findings of the study were published in the June 2 issue of New England Journal of Medicine. This marks the first vaccine study in the disease and one of the first in all cancers to show clinical benefit in a randomized Phase III clinical trial.

"This is the first time that a vaccine has shown benefit in the treatment of patients with metastatic melanoma. The trial is an early example of success with a cancer vaccine," said Dr. Howard Kaufman, director for the Rush University Cancer Center and study co-investigator.

"If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue," said Kaufman, who is also an associate dean of Rush Medical College and a professor in the departments of general surgery, internal medicine and immunology and microbiology at Rush University.

Therapeutic cancer vaccines, unlike typical vaccines that prevent infections, are meant to jump-start the immune system to help it battle existing tumors.

Rush was one of 21 centers in the U.S. participating in the trial. Researchers randomly assigned 185 patients with metastatic melanoma to either a combination of the peptide vaccine, which is a small portion of protein that is present on the surface of the melanoma cancer cells, and Interleukin-2, a drug that activates the immune system, or a high dose of Interleukin-2 alone.

The peptide vaccine, known as gp100:209-217 (200M), works by stimulating the patient's T-cells, which is known for controlling immune responses. The injection primes the immune system to recognize the protein and activates the body's cytotoxic T-cells to recognize the antigens on the surface of the cancerous tumor. The T-cells then secrete enzymes to seek out and destroy the tumor cell's membrane.

The immune-boosting drug, Interleukin-2, enhances the vaccine's effectiveness by stimulating the production of lymphocytes, a type of white blood cell that circulates throughout the body. More circulating lymphocytes means there are more cells available to do the job the vaccine has educated them to do.

Ninety-four patients in the Interleukin-2 arm of the study were enrolled and 93 were treated and evaluated for response. In the Interleukin-2 and peptide vaccine combination arm of the study, 91 were enrolled, 86 were treated and 85 were evaluated for response.

About 16 percent of study participants given the vaccine and Interleukin-2 combination saw tumors shrink by 50 percent or more, compared to 6 percent given Interleukin-2 alone.

Those in the vaccine and drug combination group also had slightly longer progression-free survival rates of 2.2 months compared to 1.6 months, which means those participants had more time in which the tumor did not grow.

Patients given the combination also lived an average of nearly seven months longer than those only give Interleukin-2 -- 17.8 months longer compared to 11.1 months.

In order for this vaccine to work, patients had to have a particular tissue type, called HLA-A2, which is present in about half of whites.

According to the American Cancer Society, melanoma has one of the fastest growing incident rates of all cancers. The five-year survival rate for melanoma patients is less than 10 percent.

Interleukin-2 is already FDA-approved to treat metastatic melanoma and kidney cancer.

The next step is to improve the vaccine's efficacy. Researchers hope to improve upon the study's findings by combining the vaccine with other immune-stimulatory agents such as adjuvants, other cytokines and antibodies that further activate the immune cells.

"This is one of the first positive, randomized vaccine trials in cancer and the findings represent a significant step forward for treatment of advanced melanoma," said Kaufman.

The vaccine, if eventually approved by the FDA, would be relatively inexpensive because it is based on a protein that's present in most melanoma cancers, whereas other vaccines have had to be created for each individual patient.


'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Therapeutic melanoma vaccine improves response rate, progression-free survival
4. Melanoma Vaccine Shows Promise in Trial
5. Vaccine increases disease-free survival for follicular lymphoma patients
6. Black Americans With Lupus Have Better Response to Flu Vaccine
7. African-Americans with SLE more responsive to flu vaccine than patients of European descent
8. Toward a vaccine for methamphetamine abuse
9. Model developed to improve combination vaccine accessibility worldwide
10. Rino Rappuoli honored for his work in vaccines and vaccinology
11. Insight into HIV immunity may lead to vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... publication and community for those in the fight against cancer, has produced a ... their success. HRA will release top-line findings in a webinar, Defining Compassionate ...
(Date:2/23/2017)... ... (PRWEB) February ... for the nation to come together to combine its favorite ... with its favorite fruit – apples! To celebrate National Nutrition ... join the “Apple Madness” bracket tournament – a five-week, five-round ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz ... a new Indiegogo campaign . Individuals are now able to contribute to the ... area, either as a participating patient or through an Indiegogo donation. The entirety of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... it will release fourth quarter and yearly financial ... 2017. AcelRx management will host an investment-community conference ... Pacific Time) on March 2 nd 2017 ...
(Date:2/23/2017)... ... has announced the addition of the "Global Antifungal Drugs Market Analysis ... The Global Antifungal Drugs Market is poised to grow ... approximately $12.8 billion by 2025. This industry report ... global as well as regional levels presented in the research scope. The ...
(Date:2/23/2017)... 2017 The top three players ... Healthcare, Koninklijke Philips N.V., and Schiller. Collectively, these companies ... market in 2015. Strong product portfolio and a monumental ... be aiding these players remain leaders in the fragmented ... in the global market are likely to focus on ...
Breaking Medicine Technology: